Drugs / KGX101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07260305 | Nov 2024 → Jan 2027 expected | — | Kangabio AUSTRALIA LTD PTY | Recruiting | No outcome recorded |
| Phase 1 | NCT06074497 | Dec 2023 → May 2026 overdue | — | Kangabio AUSTRALIA LTD PTY | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-10-31 | Sanyou Biopharmaceuticals(Shanghai)Co., Ltd | Regulatory Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy sanyoubio.com ↗
On October 26, 2023, KangaBio announced that the U.S. FDA has granted official approval for their independent R&D clinical trial application (IND) for KGX101. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-10-31 | Sanyou Biopharmaceuticals(Shanghai)Co., Ltd | Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy sanyoubio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KGX101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06074497 ↗ |
| Modality | Protein / enzyme biologic | “KGX101 is a heterodimeric IL-12 prodrug” NCT07260305 ↗ |
| Route | Intravenous | “KGX101 intravenous infusion” NCT06074497 ↗ |